London and Oxford, United Kingdom (Press Release) – GlaxoSmithKline plc and Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell ther­apy to treat cancer, today announced the transition of the devel­op­ment pro­gram for GSK3377794 (GSK ‘794), an NY-ESO SPEAR T-cell ther­apy, to GSK. As a result of the transition, GSK assumes full responsibility for future research, devel­op­ment, and poten­tial com­mer­cial­iza­tion of this pioneering ther­apy, and Adaptimmune will receive $27.5 million (£21.2 million) from GSK.

Dr. Hal Barron, Pres­i­dent R&D, GSK said, “The data we’ve seen for GSK ‘794 point to the poten­tially transformational …